102721-76-6

Basic information

• Product Name: 2-methylamino-2-methylthio-1-nitroethene
• CAS NO: 102721-76-6
• Molecular Weight: 148.186
• Mol File: 102721-76-6.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 2-methylamino-2-methylthio-1-nitroethene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methylamino-2-methylthio-1-nitroethene(102721-76-6)
• EPA Substance Registry System: 2-methylamino-2-methylthio-1-nitroethene(102721-76-6)

Safety Data

• Hazardous Substances Data: 102721-76-6(Hazardous Substances Data)

Upstream product

• 75-52-5 nitromethane 
• 18805-25-9 methyl carbonimidodithioic acid dimethyl ester 
• 74-89-5 methylamine 
• 13623-94-4 1,1-di(methylsulfanyl)-2-nitroethylene 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 54252-45-8 N,N'-dimethyl-2-nitro-1,1-ethenediamine 
• 1585972-07-1 1,4-dihydro-N,3-dimethyl-4-(naphthalen-2-yl)-5-nitro-1-phenylpyrano[2,3-c]pyrazol-6-amine 
• 1585972-01-5 4-(2,4-dichlorophenyl)-1,4-dihydro-N,3-dimethyl-5-nitropyrano[2,3-c]pyrazol-6-amine 
• 1585972-02-6 4-(4-fluorophenyl)-1,4-dihydro-N,3-dimethyl-5-nitropyrano[2,3-c]pyrazol-6-amine 
• 1585972-03-7 4-(4-bromophenyl)-1,4-dihydro-N,3-dimethyl-5-nitropyrano[2,3-c]pyrazol-6-amine 
• 1585972-05-9 1,4-dihydro-N,3-dimethyl-5-nitro-4-(2-nitrophenyl)-1-phenylpyrano[2,3-c]pyrazol-6-amine 
• 1585972-04-8 1,4-dihydro-N,3-dimethyl-5-nitro-4-(2-nitrophenyl)pyrano[2,3-c]pyrazol-6-amine 
• 1585971-90-9 3-methyl-4-(2-(methylamino)-3-nitro-4H-chromen-4-yl)-1-phenyl-1H-pyrazol-5-ol 
• 1585971-91-0 4-(6,8-dibromo-2-(methylamino)-3-nitro-4H-chromen-4-yl)-3-methyl-1-phenyl-1H-pyrazol-5-ol 
• 1585971-92-1 3-methyl-4-(2-(methylamino)-3,6-dinitro-4H-chromen-4-yl)-1-phenyl-1H-pyrazol-5-ol 
• 1585971-93-2 4-(7-methoxy-2-(methylamino)-3-nitro-4H-chromen-4-yl)-3-methyl-1-phenyl-1H-pyrazol-5-ol 
• 1585972-06-0 4-(2-fluorophenyl)-1,4-dihydro-N,3-dimethyl-5-nitro-1-phenylpyrano[2,3-c]pyrazol-6-amine 
• 1585971-96-5 1,4-dihydro-N,3-dimethyl-5-nitro-4-p-tolylpyrano[2,3-c]pyrazol-6-amine 
• 1585971-97-6 1,4-dihydro-N,3-dimethyl-5-nitro-4-(4-nitrophenyl)pyrano[2,3-c]pyrazol-6-amine 

Relevant articles and documents

Synthesis of Spiro[indoline-3,4′-pyrano[3,2-c]chromene]diones

A new series of isatin-based spiro-fused derivatives were prepared, via three-component reaction of N-alkyl-1-(methylthio)-2-nitroethenamine derived from the addition of various amines to nitroketene dithioacetal with isatin derivatives and 4-hydroxycouma

Rapid and catalyst free synthesis of new bis(benzo[: G] chromene) and bis(pyrano[3,2- c] chromene) derivatives and optimization of reaction conditions using response surface methodology

4,4′-(1,4-phenylene)bis(2-(alkylamino)-3-nitro-4H-benzo[g]chromene-5,10-dione) and 4,4′-(1,4-phenylene)bis(2-(alkylamino)-3-nitropyrano[3,2-c]chromen-5(4H)-one) derivatives are synthesized by a one-pot, multi-component reaction of N-alkyl-1-(methylthio)-2

A simple and environmentally benign synthesis of novel spiro[indoline-3,5′-pyrano[2,3-d]pyrimidine] derivatives in water

Abstract: A green, convenient, and efficient one-pot synthesis of a new class of spiro[indolinepyranopyrimidine] derivatives was achieved in good yields by the multi-component reaction of N-alkyl-1-(methylthio)-2-nitroethenamine derived from the addition

POLYFLUORINATED COMPOUNDS ACTING AS BRUTON TYROSINE KINASE INHIBITORS

Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are Bruton's tyrosine kinase (BTK) inhibitors. These compounds may possess better BTK inhibition selectivity and pharmacokinetic properties. Disclosed herein are the synthesis methods of these compounds. Disclosed herein are novel synthesis methods of the multi-fluoro-substituted benzophenone and substituted phenoxy benzene. Also disclosed are pharmaceutical compositions comprising the BTK inhibitors described herein. The present invention also relates to pharmaceutical formulations comprising the compounds described herein as active ingredients. The present invention also includes the therapeutic methods by administering the BTK inhibitors and their formulations to treat and inhibit autoimmune disease, hypersensitivity disease, inflammatory diseases and cancer.